Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

Symphogen buys tumor blocking technology

The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.

Faster sales but less profits for Probi

The probiotic company increases its turnover, and the net results are twice as large as last year.

Orexo opens doors eastwards

The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal

Success fee to Bioinvent and partner

The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.

Danisco strengthens its IP team

Danisco's division Genencor has appointed a new Vice President of Intellectual Property Strategy and Chief IP Counsel.

Dako appoints new CEO

The Danish cancer therapeutic company Dako has appointed a new CEO after Patrik Dahlén.

Finnish Innovation Fund gets new leader

The Supervisory Board of the Finnish Innovation Fund Sitra has appointed members of the Board, including a new president.

Pharma is a safe market

Pharma is the best industry to invest in. That states leaders from risk capital companies, interviewed by the Economist Intelligence Unit.

Medicult disclaims Swedish offer

The Norwegian company Medicult's Board is highly sceptical to the yesterday announced Vitrolife offer.

LEO Pharma - International Clinical Trial Manager

Parnevik firm in Swiss osteoporosis deal

The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.

SDU professor helps EU

Mette Præst Knudsen from the University of Southern Denmark, SDU, has been appointed as an expert member in an EU politics group.

New CEO to Swedish Tillotts Pharma

The Swiss company Tillotts Pharma's newly established Swedish organisation has appointed a CEO from Bayer Scandinavia.

New faces in Pronova Biopharma team

The Norwegian company Pronova Biopharma has recently changed the management team structure.

New Nordic biotech company

The Swiss biotech company Tillots Pharma opens a office in Stockholm, which will be run under private management.

New management at Øresund

The Øresund University has recently appointed a new director and a new Chairman.

Time to save for survival

The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.

Bring talent to those in need

Ho ho ho, Christmas time is here again. So get busy decking the halls, perhaps not with assorted greenery, but with something of a more lasting value.